Valuation: BioRegenx, Inc.

Market Cap 5.3M 4.66M 4.4M 3.99M 7.5M 508M 7.54M 52.73M 20.36M 259M 19.88M 19.45M 833M P/E 2024
-0.37x
P/E 2025 -8.02x
Enterprise Value 7.44M 6.54M 6.19M 5.61M 10.54M 714M 10.6M 74.09M 28.61M 364M 27.93M 27.33M 1.17B EV / Sales 2024
4.58x
EV / Sales 2025 7.85x
Free-Float
25.48%
Yield 2024 *
-
Yield 2025 -
1 day-16.15%
1 week-8.33%
Current month-31.25%
1 month-31.25%
3 months-40.22%
6 months-47.12%
Current year-57.36%
1 week 0.01
Extreme 0.00545
0.01
1 month 0
Extreme 0.0025
0.01
Current year 0
Extreme 0.0025
0.02
1 year 0
Extreme 0.0025
0.02
3 years 0
Extreme 0.0025
0.08
5 years 0
Extreme 0.0025
0.08
10 years 0
Extreme 0.0025
0.08
Manager TitleAgeSince
Chief Executive Officer 57 08/03/2024
Corporate Secretary 69 08/03/2024
Director TitleAgeSince
Director/Board Member 71 01/01/2012
Director/Board Member 57 08/03/2024
Director/Board Member 61 08/03/2024
Date Insider Type Main position Quantity % Market Cap. Importance
08/03/24 Other

Director

9,349,568 3.3783%
08/03/24 Other

Company Secretary

108 0.0022%
08/03/24 Other

Director

416,000 0.1503%
Change 5-day change 1-year change 3-year change Capi.($)
-16.15%-8.33%-58.02% - 5.3M
-0.42%-2.12%-24.27%+2.73% 175B
+0.34%-3.38%-5.66%+12.66% 113B
-1.11%-3.98%-1.36%+66.19% 58.57B
-0.18%+1.28%-0.54%-30.35% 50.07B
+0.45%+4.36%+15.64%+53.13% 49.92B
-0.23%-3.38%+29.64%-9.74% 32.69B
+1.60%+10.15% - - 30.44B
+1.85%+4.15%+44.75%-0.60% 26.07B
+1.98%+7.44%+26.63%-1.90% 23.55B
Average -1.19%+0.67%+2.98%+11.51% 56B
Weighted average by Cap. +0.08%+0.01%-2.76%+12.36%

Financials

2024 2025
Net sales 2.34M 2.06M 1.95M 1.77M 3.32M 225M 3.33M 23.3M 9M 115M 8.79M 8.6M 368M 1.85M 1.63M 1.54M 1.4M 2.63M 178M 2.64M 18.47M 7.13M 90.84M 6.96M 6.81M 292M
Net income -23.05M -20.28M -19.17M -17.39M -32.66M -2.21B -32.85M -230M -88.66M -1.13B -86.55M -84.68M -3.63B -1.54M -1.36M -1.28M -1.16M -2.19M -148M -2.2M -15.37M -5.94M -75.61M -5.8M -5.67M -243M
Net Debt 2.11M 1.85M 1.75M 1.59M 2.98M 202M 3M 20.97M 8.1M 103M 7.91M 7.74M 331M 2.15M 1.89M 1.78M 1.62M 3.04M 206M 3.06M 21.36M 8.25M 105M 8.05M 7.88M 338M
Logo BioRegenx, Inc.
BioRegenx, Inc. operates as a holding company specializing in acquiring intellectual property (IP) and companies engaged in regenerative biotherapeutics and anti-aging research. The Company’s subsidiaries include DocSun BioMedical Holdings, Inc. (DocSun), Microvascular Health Solutions, LLC (MVHS), MyBodyRx, LLC (MyBodyRx), NuLife Sciences, Inc. (NuLife) and Findit Ai Connect, Inc. (Findit Ai). DocSun combines three technologies in the DocSun Artificial Intelligence (AI) Engine. The DocSun AI Engine integrates advanced ballistocardiography, which can detect an individual's heartbeat without touch, and photoplethysmography, a method that uses light to track the flow of blood. MVHS specializes in research, product development, sales, and education, notably producing the patented Endocalyx Pro dietary supplement. MVHS also manufactures and distributes the patented GlycoCheck software and Class 1 medical devices. DocSun is also developing an app for NuLife, TruScan.Ai mobile app/Website.
Employees
-
Date Price Change Volume
25/09/26 $0.005450 -16.15% 225
21/09/26 $0.006500 +8.33% 75,000
  1. Stock Market
  2. Stocks
  3. BRGX Stock